Marizyme Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Marizyme Inc (MARZ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Marizyme Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 42,594M combined for tracked competitors (0.0% combined share).
- Scale: Marizyme Inc ranks #32 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.5% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Marizyme Inc vs. its Competitors, Q3 2024
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Marizyme Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Marizyme Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Marizyme Inc's competitor groups requires a Commercial License.
Marizyme Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Marizyme Inc | - | - | - | Yes |
| Competitors combined (10) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MARZ Stock Performance relative to its Competitors
MARZ Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Amgen Inc | 282.9% | Outperformed |
| 2 | Harvard Apparatus Regenerative Technology Inc | 282.9% | Outperformed |
| 3 | Cellectis S a | 282.9% | Outperformed |
| 4 | Longevity Health Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Marizyme Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Marizyme Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Marizyme Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Marizyme Inc | 4,912.38 | 0.65 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Catalent Inc | 11,553.36 | 4,422.00 |
| Cellectis S a | 148.41 | 72.95 |
| Harvard Apparatus Regenerative Technology Inc | 78.23 | 0.89 |
| Vycor Medical Inc | 2.24 | 1.81 |
| SUBTOTAL | 244,159.24 | 42,600.79 |
Sign in to see all competitors of Marizyme Inc .
Sources: Marizyme Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Marizyme Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Marizyme Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Catalent Inc | PharmaConsumerHealth 55.03 % |
| Harvard Apparatus Regenerative Technology Inc | Consumer Health Products 100.00 % |
| Vycor Medical Inc | Vycor Medical Inc 95.93 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Marizyme Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Marizyme Inc | 4,912 | - | - |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Catalent Inc | 11,553 | 261,657 | -24,438 |
| Cellectis S a | 148 | 318,555 | -295,166 |
| Harvard Apparatus Regenerative Technology Inc | 78 | 110,625 | -851,375 |
| Vycor Medical Inc | 2 | 258,210 | -8,561 |
| PEERS TOTAL | 239,247 | 1,409,154 | 269,425 |
Marizyme Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Catalent Inc | North America 64.32 % |
| Vycor Medical Inc | US 99.66 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Marizyme Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Marizyme Inc's industry classification, broader than the peer set above. Market cap in millions of $.Marizyme Inc ranks #32 of 222 companies by market capitalization in its industry, holding 0.45 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 587, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 145,832 | 13.38 % |
| 2 | Medtronic Plc | 113,372 | 10.40 % |
| 3 | Stryker Corp | 105,405 | 9.67 % |
| 4 | 3m Company | 88,542 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 32 | Marizyme Inc | 4,944 | 0.45 % |
Market cap and industry share for the rest of Marizyme Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Marizyme Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 27 | Msa Safety Inc | 7,090 | 8.46 % |
| 28 | Bausch and Lomb Corp | 5,919 | 36.20 % |
| 29 | Stevanato Group S p a | 5,553 | -16.45 % |
| 30 | Teleflex Incorporated | 5,448 | 6.66 % |
| 31 | Merit Medical Systems Inc | 1,234 | 12.3% |
| 32 | Marizyme Inc | 4,944 | 8.80 % |
| 33 | Haemonetics Corporation | 1,234 | 12.3% |
| 34 | Lifestance Health Group Inc | 1,234 | 12.3% |
| 35 | Integer Holdings Corporation | 1,234 | 12.3% |
| 36 | Heartflow Inc | 1,234 | 12.3% |
| 37 | Livanova Plc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Marizyme Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Marizyme Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 70.50 % | 53.35 % (avg) | +17.1 pp |
| Operating Margin | -7,347.42 % | industry median | -7,330.9 pp |
| EBITDA Margin | -9,680.05 % | -6.82 % (avg) | -9,673.2 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 5.43 % (avg) | -5.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Marizyme Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | -4,195.09 % |
| Return on Invested Capital | -1.86 % | -7.72 % | -8.96 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Marizyme Inc's BCG Growth-Share Matrix
Relative market share (vs Marizyme Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Marizyme Inc falls in the Dog quadrant: relative market share of 0.03x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Marizyme Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 587 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 5.43 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Marizyme Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Marizyme Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Marizyme Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Marizyme Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Marizyme Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 7,330.9 points below the industry median.
- Return on equity 256.5 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.03x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-10.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Marizyme Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Marizyme Inc | 0.00 | 0.03 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Catalent Inc | 0.25 | 2.50 | 1.63 |
| Cellectis S a | 0.42 | 1.76 | - |
| Harvard Apparatus Regenerative Technology Inc | 0.73 | 1.03 | 0.10 |
| Vycor Medical Inc | 0.02 | 0.12 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Marizyme Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Marizyme Inc | Q3 2024 | - | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Catalent Inc | Q3 2024 | +4.2 % | - |
| Cellectis S a | Q4 2025 | +75.8 % | - |
| Harvard Apparatus Regenerative Technology Inc | Q1 2026 | +402.2 % | - |
| Vycor Medical Inc | Q2 2026 | -15.7 % | - |
| PEERS TOTAL | +9.3 % | +266.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Marizyme Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Marizyme Inc | Q3 2024 | - | - |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Catalent Inc | Q3 2024 | +3.6 % | -32.1 % |
| Cellectis S a | Q4 2025 | - | -8.6 % |
| Harvard Apparatus Regenerative Technology Inc | Q1 2026 | +524.2 % | - |
| Vycor Medical Inc | Q2 2026 | -9.0 % | - |
Marizyme Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Marizyme Inc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Catalent Inc | - | - | - |
| Cellectis S a | - | - | - |
| Harvard Apparatus Regenerative Technology Inc | - | - | - |
| Vycor Medical Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Marizyme Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Marizyme Inc | - | 7,606.54 |
| Amgen Inc | 25.97 | 5.97 |
| Catalent Inc | - | 2.61 |
| Cellectis S a | - | 2.03 |
| Harvard Apparatus Regenerative Technology Inc | - | 88.40 |
| Vycor Medical Inc | - | 1.24 |
| PEERS AVERAGE | 30.08 | 5.73 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.